RT Journal Article
SR Electronic
T1 Trait mindfulness is associated with less amyloid, tau, and cognitive decline in individuals at risk for Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.17.21257320
DO 10.1101/2021.05.17.21257320
A1 Cherie Strikwerda-Brown
A1 Hazal Ozlen
A1 Alexa Pichet Binette
A1 Marianne Chapleau
A1 Natalie L. Marchant
A1 John C. S. Breitner
A1 Sylvia Villeneuve
A1 for the PREVENT-AD Research Group
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.17.21257320.abstract
AB Mindfulness, defined as the ability to engage in non-judgmental awareness of the present moment, has been associated with an array of health benefits. Mindfulness may also represent a protective factor for Alzheimer’s disease (AD). Here, we tested the potential protective effect of trait mindfulness on cognitive decline and AD pathology in older adults at risk of AD dementia. Measures of trait mindfulness, longitudinal cognitive assessments, and Aβ-and tau-positron emission tomography (PET) scans were collected in 261 nondemented older adults with a family history of AD dementia from the PREVENT-AD observational cohort study. Multivariate partial least squares analyses were used to examine relationships between combinations of different facets of trait mindfulness and (1) cognitive decline, (2) Aβ, and (3) tau. Higher levels of trait mindfulness, particularly mindful nonjudgment, were associated with less cognitive decline, Aβ, and tau. Trait mindfulness may represent a psychological protective factor for AD dementia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Canada Research Chair, a Canadian Institutes of Health Research Foundation Grant, a Canada Fund for InnovationGrant, and an Alzheimer's Association Grant (to SV). PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Quebec-Sante, an unrestricted research grant from Pfizer Canada, the Levesque Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for InnovationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board at McGill UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be released upon reasonable request